Eli Lilly and Company announced positive results from the Phase 3 LIBRETTO-432 clinical trial evaluating Retevmo® (selpercatinib) as adjuvant therapy versus placebo in early-stage (II–IIIA) RET fusion-positive lung cancer.
Selpercatinib showed a statistically significant improvement in event-free survival (EFS) as adjuvant therapy in patients with early-stage RET fusion-positive NSCLC. Overall survival trended positively (data immature), and safety was consistent with prior trials.
Detailed results will be shared at an upcoming medical meeting.
These results also reinforce the importance of genomic testing at diagnosis. Identifying RET fusions helps ensure patients can access personalized treatments designed for their cancer. Advances like this bring hope and move us closer to better outcomes for people living with early stage RET-positive lung cancer.
LIBRETTO-432 clinical trial: https://clinicaltrials.
